Literature DB >> 19169498

Cryptic intragenic deletion of the SHOX gene in a family with Léri-Weill dyschondrosteosis detected by Multiplex Ligation-Dependent Probe Amplification (MLPA).

Mariana F A Funari1, Alexander A L Jorge, Emilia M Pinto, Ivo J P Arnhold, Berenice B Mendonca, Mirian Y Nishi.   

Abstract

LWD is associated to SHOX haploinsufficiency, in most cases, due to gene deletion. Generally FISH and microsatellite analysis are used to identify SHOX deletion. MLPA is a new method of detecting gene copy variation, allowing simultaneous analysis of several regions. Here we describe the presence of a SHOX intragenic deletion in a family with LWD, analyzed through different methodologies. Genomic DNA of 11 subjects from one family were studied by microsatellite analysis, direct sequencing and MLPA. FISH was performed in two affected individuals. Microsatellite analysis showed that all affected members shared the same haplotype suggesting the involvement of SHOX. MLPA detected an intragenic deletion involving exons IV-VIa, which was not detected by FISH and microsatellite analysis. In conclusion, the MLPA technique was proved to be the best solution on detecting this small deletion, it has the advantage of being less laborious also allowing the analysis of several regions simultaneously.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19169498     DOI: 10.1590/s0004-27302008000800029

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  3 in total

1.  Identification of a novel 15.5 kb SHOX deletion associated with marked intrafamilial phenotypic variability and analysis of its molecular origin.

Authors:  Angelos Alexandrou; Ioannis Papaevripidou; Kyriakos Tsangaras; Ioanna Alexandrou; Marios Tryfonidis; Violetta Christophidou-Anastasiadou; Eleni Zamba-Papanicolaou; George Koumbaris; Vassos Neocleous; Leonidas A Phylactou; Nicos Skordis; George A Tanteles; Carolina Sismani
Journal:  J Genet       Date:  2016-12       Impact factor: 1.166

2.  Effectiveness of the combined recombinant human growth hormone and gonadotropin-releasing hormone analog therapy in pubertal patients with short stature due to SHOX deficiency.

Authors:  Renata C Scalco; Suzana S J Melo; Patricia N Pugliese-Pires; Mariana F A Funari; Mirian Y Nishi; Ivo J P Arnhold; Berenice B Mendonca; Alexander A L Jorge
Journal:  J Clin Endocrinol Metab       Date:  2009-11-19       Impact factor: 5.958

Review 3.  Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases.

Authors:  Liborio Stuppia; Ivana Antonucci; Giandomenico Palka; Valentina Gatta
Journal:  Int J Mol Sci       Date:  2012-03-08       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.